CytoMed Therapeutics (GDTC) Common Equity (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Common Equity of $5.3 million for Q4 2025, down 26.78% sequentially from $7.2 million in Q2 2025, and down 21.55% YoY from $6.7 million in Q4 2024.
CytoMed Therapeutics (GDTC) Common Equity (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Common Equity for 5 years, with the latest figure at $5.3 million in Q4 2025.
- Quarterly Common Equity fell 21.55% year-over-year to $5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.3 million (down 21.55% YoY) and the FY2025 annual result came in at $5.1 million, down 24.18% from the prior year.
- Common Equity retreated to $5.3 million in Q4 2025 per GDTC's latest filing, from $7.2 million in the prior quarter.
- Over five years, Common Equity peaked at $13.2 million in Q2 2023 and troughed at $422464.0 in Q4 2022.
- A 5-year average of $6.7 million and a median of $7.0 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity sank 77.88% in 2022, then soared 1871.4% in 2023.
- Over 5 years, Common Equity stood at $1.9 million in 2021, then tumbled by 77.88% to $422464.0 in 2022, then jumped by 1871.4% to $8.3 million in 2023, then declined by 19.07% to $6.7 million in 2024, then dropped by 21.55% to $5.3 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $5.3 million, $7.2 million, and $6.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | 5.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.29 Mn |
| Jun 30, 2025 | 7.22 Mn |
| Dec 31, 2024 | 6.74 Mn |
| Jun 30, 2024 | 10.16 Mn |
| Dec 31, 2023 | 8.33 Mn |
| Jun 30, 2023 | 13.17 Mn |
| Dec 31, 2022 | 422,464.04 |
| Dec 31, 2021 | 1.91 Mn |